Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 31

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 31
---
 purchase, up to $35.0 million of newly issued Depositary Shares over a 36-month period, unless the ELOC is terminated in accordance with its terms. As of June 30, 2025, we have sold 51,468,000,000 Ordinary Shares under the ELOC, for gross proceeds of approximately $8.6 million, andissued 1,794,060,000 Ordinary Shares to C/M in satisfaction of a commitment fee.

On May 15,
2025, we entered into the 2025 Warrant Agreements with certain holders of our outstanding Series E Warrants, Series H Warrants, Series
J Warrants, and Series K Warrants issued in prior transactions, pursuant to which the holders agreed to exercise certain of such warrants
in exchange for a reduction in exercise price of each warrant to $3.10 per share. An aggregate of 20,041 warrants were exercised for
aggregate gross proceeds of approximately $62,000, before estimate offering expenses.

Since their
respective dates of issuance, we have issued 1,529,030,000 Ordinary Shares upon exercises of the Series H Warrants, Series J Warrants
and Series K Warrants, including warrants exercised pursuant to the terms of the 2025 Warrant Agreements (other than shares held in abeyance).

On June 11,
2025, we held the June 2025 GM and our shareholders passed resolutions to, among other things, subdivide our Ordinary Shares of £0.00005
nominal value each into one Ordinary Share of £0.000001 nominal value and 49 D Deferred Shares of £0.000001 nominal value
each.

On July 31,
2025, we effected a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 10,000 Ordinary Shares per
Depositary Share to 100,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

Options

We have established
the Biodexa Pharmaceuticals PLC Enterprise Management Incentive and Unapproved Option Scheme, or the Plan, to
allow us to grant options to purchase Ordinary Shares (in the form of Depositary Shares) to employees and directors of the Company or
any of its subsidiaries for the purpose of attracting, rewarding and retaining such persons. The Plan was originally adopted in December
2014 and amended on April 11, 2024 to govern the grant of tax-advantaged enterprise management incentive stock options and unapproved